Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Media Farmasi : Jurnal Ilmu Farmasi (Journal Of Pharmaceutical Science) Indonesian Journal of Cancer
Putri, Risani Andalasia
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
An Overview of Antiemetic Prophylaxis for Chemotherapy Induced Nausea and Vomiting in Head and Neck Cancer Patients at Dharmais National Cancer Hospital Sari, Novita; Sauriasari, Rani; Putri, Risani Andalasia
Indonesian Journal of Cancer Vol 19, No 2 (2025): June
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v19i2.1361

Abstract

Background: Chemotherapy-induced nausea and vomiting (CINV) are frequently experienced by cancer patients. One of the antineoplastic agents with high emetogenicity is cisplatin. Cisplatin is commonly used in the treatment of head and neck cancer (HNC). Therefore, the use of prophylactic antiemetics is recommended. This study aimed to examine the use of antiemetics as prophylaxis for CINV in HNC patients.Method: This study is a cross-sectional, using retrospective data from medical record observations at Dharmais National Cancer Hospital. Purposive sampling was used to collect data on antiemetic use between October and December of 2023. All patients with HNC who were undergoing chemotherapy and receiving antiemetics as prophylaxis during this period were included in the study and analyzed descriptively.Results: A total of 177 chemotherapy cycles in 96 head and neck cancer patients included in this study indicated that the most commonly used prophylactic antiemetic was a combination of ondansetron and dexamethasone (83.1%). The experience of CINV occurred more frequently in the delayed phase, with nausea occurring in 64.4% and vomiting in 44.6%. The highest severity level of nausea occurred at grade 2 (50.8%), meanwhile vomiting occurred at grade 1 (55.9%).Conclusion: The findings of this study show that the use of 5-HT3 RA (ondansetron) and dexamethasone alone is not sufficient to reduce the CINV response, thus requiring additional therapy such as D-2 RA, PPI, and H-2 Blockers.
EVALUASI PENGGUNAAN OBAT ANTIMUNTAH PADA PASIEN ANAK PENDERITA KANKER DI RUMAH SAKIT KANKER DHARMAIS JAKARTA PERIODE JUNI-JULI 2016 Elvina, Ridha; Musyarofah, Rahma; Putri, Risani Andalasia
Media Farmasi: Jurnal Ilmu Farmasi Vol. 14 No. 1: Maret 2017
Publisher : Universitas Ahmad Dahlan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.12928/mf.v14i1.9829

Abstract

Penyakit kanker rmerupakan salah satu penyebab kematian utama di seluruh dunia. Pada tahun 2012, kanker menjadi penyebab kematian sekitar 8,2 juta orang. Salah satu pengobatan kanker yaitu dengan cara kemoterapi. Efek samping yang paling besar dari pengobatan dengan cara kemoterapi adalah gangguan mual dan muntah. Penelitian ini bertujuan untuk mengevaluasi keberhasilan terapi pengobatan antimuntah didasarkan pada ketepatan pemilihan obat, dosis serta efek terapi yang dihasilkan. Metode yang digunakan bersifat deskriptif prospektif yaitu dengan memantau langsung penggunaan antimuntah pada pasien kanker anak paska kemoterapi di ruang rawat inap Rumah Sakit Kanker Dharmais Jakarta selama periode penelitian Juni-Juli 2016. Dari 35 pasien yang masuk kedalam kriteria inklusi, terlihat sebanyak 97,14% pasien mendapatkan obat antimuntah dengan dosis yang sesuai, dan sebanyak 100%  pasien mendapatkan obat yang sesuai.
Co-Authors Elvina, Ridha Musyarofah, Rahma Novita Sari Rani Sauriasari, Rani